We have published revised versions of the OMRON Privacy Policy and Cookie Policy. Your use of our products and services is subject to these revised terms.

This website uses cookies. By continuing to browse through this website, you agree to our Cookie Policy which has been revised in May 2018.

Allow cookies

News Releases & Events

RS7 Intelli IT, OMRON’s First Automatic Wrist Blood Pressure Monitor Clinically Validated for Use in Obese Population

Due to the fast-growing prevalence of obesity as a burden of cardiovascular risk, empowering obese people to make informed decisions about their health becomes critical. This is now possible with this new OMRON wrist blood pressure monitor, the clinical validation for use in obese population of which was announced at the ESC Congress 2018 in Munich.

HOOFDDORP, August 28, 2018 – According to the International Society of Hypertension, high blood pressure causes over 10 million deaths each year and is the most significant single contributing risk factor to global death . This is especially worrying in the case of obese people, because obesity is a major cause of hypertension, accounting for 65-75% of the risk for essential hypertension . Following a study by Framingham, 78% of hypertension in men and 65% in women can be attributed to excess weight gain . With obesity rising fast as a burden of cardiovascular risk -it went from the fifth to the third position between 2000 and 2013 -, controlling hypertension in obese individuals is crucial.

However, obtaining accurate readings in this subgroup with traditional devices has been so far challenging: large and extra-large cuffs and bladders in most home blood pressure monitors are scarce, cone-shaped arms make difficult or impossible to wrap the arm with a thigh cuff evenly (and therefore, blood pressure is overestimated) and subcutaneous adiposity thickness affects the artery compression and thus can lead to incorrect readings.

Now, OMRON RS7 Intelli IT, which will be available for consumers later this year, extends OMRON’s long-standing tradition of accuracy and relentless pursue of quality to the field of wrist blood pressure monitors. Therefore, obese people will gain accurate readings of their blood pressure, to make -together with their Doctor- informed medical and lifestyle decisions. Naturally, it is also validated for use in the general population and fits people of all shapes.

According to the protocol set by the European Society of Hypertension, the clinical validation of the OMRON RS7 Intelli IT, carried out by Dr. Roland Asmar and presented at the ESC Congress 2018 in Munich, demonstrated accurate results equivalent to those obtained in the doctor’s office. In correlation with these results, the ESC/ESH Guidelines for the Management of Arterial Hypertension –whose new version was released at ESC 2018- recommend the use of wrist devices to accurately measure blood pressure in obese patients.

“OMRON firmly believes in the need to go further than just getting clinical validation in the general population but also carrying out trials in specific populations such as the obese, pregnant women and diabetic patients. The results from the clinical validation in obese people have strongly confirmed our beliefs and we are proud to offer more and more professionalized devices over time”, said Lucia Prada, Marketing Director of OMRON Healthcare Europe.

 

A new wrist range that brings unique benefits for consumers

 

One of the most frequent concerns about the wrist devices is that an incorrect positioning affects the accuracy of the reading. This is no longer the case with OMRON RS7 Intelli IT, since it is equipped with an advanced, one of a kind LED positioning sensor, which flashes if the arm is not correctly positioned. To add more, the new OMRON RS7 Intelli IT syncs with the OMRON connect app, so that users can track their progress over time and it’s completely silent. It also includes blood pressure level indicator, irregular heart beat detection, body movement detection and average function, stores up to 100 memories and allows 2 users.

In addition to the RS7 Intelli IT, OMRON will launch a whole new range of wrist devices, clinically validated for use in the general population, featured with different functions, to address various types of needs and lifestyle. The whole range is easy to use on the wrist, tubeless, small and portable, ideal for travelling, sleek and compact.

This new technology is part of a series of developments deeply rooted in OMRON’s Japanese heritage of innovation. Designing wearables to be used on the go, OMRON is enabling patients to get real-time insights on their situation, so that they can be in control of their body and make appropriate medical and lifestyle decisions to live with zero compromise on health.

 

###

 

ABOUT OMRON HEALTHCARE

Committed to helping people live more active and fulfilling lives with zero compromise, OMRON Healthcare is a global leader in the field of clinically proven, innovative medical equipment for health monitoring and therapy.

Throughout its 85-year history OMRON Healthcare has been striving to improve lives and contribute to a better society by developing innovations that help people prevent, treat and manage their medical conditions, both at home and in clinical practice in over 117 countries.

OMRON Healthcare is the Global No.1 brand in both blood pressure monitors, with over 200 million units sold, as well as nebulizers for respiratory treatment with over 30 million devices sold. The company’s additional core product categories are low-frequency pain therapy equipment, body composition monitors and electronic thermometers.

OMRON Healthcare Group is headquartered in Kyoto, Japan. OMRON Healthcare Europe B.V. is the healthcare division for Europe, Russia, Middle East and Africa and provides services to customers in more than 74 countries.

OMRON Healthcare Europe B.V.
Scorpius 33, 2132 LR Hoofddorp, The Netherlands
+31 (0)23 55 44 700
info.omronhealthcare@eu.omron.com

References:

1 Obtained from www.maymeasure.com
2 Obtained from www.maymeasure.com
3 (Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med. 1987;16:235–251).
4 Lancet, 2015. http://dx.doi.org/10.1016/S0140-6736